Different structural requirements for melanin-concentrating hormone (MCH) interacting with rat MCH-R1 (SLC-1) and mouse B16 cell MCH-R.

Abstract

Melanin-concentrating hormone (MCH) is a neuropeptide occurring in all vertebrates and some invertebrates and is now known to stimulate pigment aggregation in teleost melanophores and food-intake in mammals. Whereas the two MCH receptor subtypes hitherto cloned, MCH-R1 and MCH-R2, are thought to mediate mainly the central effects of MCH, the MCH-R on pigment cells has not yet been identified, although in some studies MCH-R1 was reported to be expressed by human melanocytes and melanoma cells. Here we present data of a structure-activity study in which 12 MCH peptides were tested on rat MCH-R1 and mouse B16 melanoma cell MCH-R, by comparing receptor binding affinities and biological activities. For receptor binding analysis with HEK-293 cells expressing rat MCH-R1 (SLC-1), the radioligand was [125I]-[Tyr13]-MCH with the natural sequence. For B16 cells (F1 and G4F sublines) expressing B16 MCH-R, the analog [125I]-[D-Phe13, Tyr19]-MCH served as radioligand. The bioassay used for MCH-R1 was intracellular Ca2+ mobilization quantified with the FLIPR instrument, whereas for B16 MCH-R the signal determined was MAP kinase activation. Our data show that some of the peptides displayed a similar relative increase or decrease of potency in both cell types tested. For example, linear MCH with Ser residues at positions 7 and 16 was almost inactive whereas a slight increase in side-chain hydrophilicity at residues 4 and 8, or truncation of MCH at the N-terminus by two residues hardly changed binding affinity or bioactivity. On the other hand, salmonic MCH which also lacks the first two residues of the mammalian sequence but in addition has different residues at positions 4, 5, 9, and 18 exhibited a 5- to 10-fold lower binding activity than MCH in both cell systems. A striking difference in ligand recognition between MCH-R1 and B16 MCH-R was however observed with modifications at position 13 of MCH: whereas L-Phe13 in [Phe13, Tyr19]-MCH was well tolerated by both MCH-R1 and B16 MCH-R, change of configuration to D-Phe13 in [D-Phe13, Tyr19]-MCH or [D-Phe13]-MCH led to a complete loss of biological activity and to a 5- to 10-fold lower binding activity with MCH-R1. By contrast, the D-Phe13 residue increased the affinity of [D-Phe13, Tyr19]-MCH to B16 MCH-R about 10-fold and elicited MAP kinase activation as observed with [Phe13, Tyr19]-MCH or MCH. These data demonstrate that ligand recognition by B16 MCH-R differs from that of MCH-R1 in several respects, indicating that the B16 MCH-R represents an MCH-R subtype different from MCH-R1.

• Authors: Sophie E Schlumberger, Yumiko Saito, Thomas Giller, Edith Hintermann, Heidi Tanner, Verena Jäggin, Urs Zumsteg, Olivier Civelli, Alex N Eberle
• Journal: Journal of receptor and signal transduction research (J Recept Signal Transduct Res) Vol. 23 Issue 1 Pg. 69-81 (Feb 2003) ISSN: 1079-9893 [Print] England
• PMID: 12680590 (Publication Type: Journal Article)

Chemical References

• Hypothalamic Hormones
• Melanins
• Pituitary Hormones
• Receptors, Pituitary Hormone
• Recombinant Proteins
• melanin-concentrating hormone receptor
• melanin-concentrating hormone
• Mitogen-Activated Protein Kinases

Topics

• Amino Acid Sequence
• Animals
• Calcium Signaling (drug effects)
• Cell Line
• Humans
• Hypothalamic Hormones (chemistry, genetics, metabolism, pharmacology)
• Kinetics
• Melanins (chemistry, genetics, metabolism, pharmacology)
• Melanoma, Experimental (metabolism)
• Mice
• Mitogen-Activated Protein Kinases (metabolism)
• Molecular Sequence Data
• Molecular Structure
• Pituitary Hormones (chemistry, genetics, metabolism, pharmacology)
• Rats
• Receptors, Pituitary Hormone (drug effects, metabolism)
• Recombinant Proteins (chemistry, genetics, metabolism, pharmacology)
• Structure-Activity Relationship